StockData
Provectus Biopharmaceuticals, Inc. logo

Provectus Biopharmaceuticals, Inc. (PVCT) stock

PVCTOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 4/30
$0.05+0.00 (+0.39%)

Close on Oct 19, 2026Market cap $20.55MP/E –Yield –

Provectus Biopharmaceuticals price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Provectus Biopharmaceuticals's price to sales ratio was 71.3× on Apr 30, 2026, against 63.3× a year earlier. Over the last 3 years it ranged from 39.6× to 148.9×, with a median of 67.0×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Apr 30, 202671.3×+4.2
2025Dec 31, 202567.0×−2.7
2024Dec 31, 202469.7×+2.8
2023Dec 29, 202367.0×–

More Provectus Biopharmaceuticals figures

See a number that looks wrong?